Clinical Trial

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a nonrandomized, open-label, multicenter rollover study for patients who received futibatinib as monotherapy or as combination therapy in a Taiho-sponsored futibatinib study.
Protocol Amendment History 1 change
critical Trial status changed: Enrolling by Invitation → Active, Not Recruiting 2026-07-29
Trial Details
NCT Number NCT06506955
Lead Sponsor Taiho Oncology, Inc.
Conditions Advanced/Metastatic Cancer
Enrollment 15 participants
Start Date 2024-10-01
Primary Completion 2027-04 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-28